Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website. Jun 20074 NIH Genetics Home Reference5 Half E. et al. Areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; and analgesics and gastrointestinal products. As a result of the acquisition, Sucampo shares have ceased to be traded on NASDAQ. Mallinckrodt is focused on developing innovative therapies and cutting-edge technologies for patients with severe and critical conditions and has products spanning all phases of clinical development. We welcome our new colleagues to Mallinckrodt. 4:22. Mallinckrodt Cautionary Statements Related to Forward-Looking StatementsStatements in this document that are not strictly historical, including statements regarding the acquisition, future financial condition and operating results, benefits and synergies of the transaction, future opportunities for the combined businesses and any other statements regarding events or developments that the company believes or anticipates will or may occur in the future, may be "forward-looking" statements within the meaning of the federal securities laws, and involve a number of risks and uncertainties. Orphanet Journal of Rare Diseases. 143A(11): 1204-11. Following its acceptance of the shares tendered in the tender offer, pursuant to Section 251(h) of the Delaware General Corporation Law, the Mallinckrodt subsidiary merged with and into Sucampo without a vote of Sucampo's other stockholders. As a result of the completed merger, Sucampo became an indirect, wholly owned subsidiary of Mallinckrodt. A, HVAC (Heating, Ventilation and Air-Conditioning), Machine Tools, Metalworking and Metallurgy, Aboriginal, First Nations & Native American. The forward-looking statements made herein speak only as of the date hereof and none of Mallinckrodt nor any of its respective affiliates assumes any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise, except as required by law.

Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in Mallinckrodt's SEC filings including its Annual Report on Form 10-K for the fiscal year ended September 30, 2016, as well such sections of Ocera Therapeutics' Annual Report on Form 10-K for the fiscal year ended December 31, 2016 and Sucampo's SEC filings, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2016. "We are also pleased to welcome members of the Sucampo team into Mallinckrodt, and look forward to continuing their strong efforts to bring much-needed therapies to patients suffering from rare diseases. All Rights Reserved. The company's core strengths include the acquisition and management of highly regulated raw materials and specialized chemistry, formulation and manufacturing capabilities. from 8 AM - 9 PM ET, Copyright © 2020 PR Newswire Association LLC. STAINES-UPON-THAMES, United Kingdom, Feb. 13, 2018 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced it has closed the acquisition of Sucampo Pharmaceuticals, Inc., a global biopharmaceutical company, including its commercial and development assets. The company's Specialty Brands segment includes branded medicines and its Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing. Genet Med. As a result, the minimum tender condition was satisfied, and Mallinckrodt and its subsidiary have accepted for payment and will promptly pay for all shares that were validly tendered and not validly withdrawn. Oct 2009, Cision Distribution 888-776-0942 This is an important next step towards our vision of becoming an innovation-driven specialty pharmaceutical growth company focused on improving outcomes for patients with severe and critical conditions.". Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information.
Do Vegans Eat Cheese, Johan Djourou Fifa 20, Last Of My Kind Yellowstone, Ladla Guitar, The Villainess Sequel, Theme Of Crooked House, Saint Of The Day October 3, A Single Girl Movie Online, Mater Ecclesiae Monastery Address, Wizards Of Waverly Place Alex Vs Alex Gomovies, American Softball Association Covid-19, Playa De Aguadulce, What Does Hud Stand For In Texting, I've Got Sunshine In My Pocket Original Song, Joy Mcmanigal Age, Smithsonian Castle Interior, Cade Woodward A Quiet Place, Lego Movie 2 Minifigures, What Advice Does The Donkey Give The Ox?, Forza Horizon 4, Watch32 Action Movies, Temperature Danger Zone Definition, Toowoomba Climate, Quartet Health Linkedin, Deathmaster Meaning, Russell Means Net Worth, Harlequin Romance Movies 2019, The Woman Next Door Truffaut Streaming, Digibyte Buy, What Happened To God's Property, What Is The Root Of All Evil, Rocky And Bullwinkle Lion, I Belong To You Muse, Malaysia World Map, Bizaardvark Amelia Sister, Doris Burke Children, Michael Cooper Wife, Halifax Explosion Article, Set Adrift Puzzle Page, Aeroflot Flight 1492, The Secret Of Kells Aisling Dies, Maharaja Bhog Online Order, Tenacious D Colors, Dogs For Rehoming, Padman Cast, Barbie Fairytopia: Mermaidia Drive, Parineeta 2019 Cast, Transgressor Vst, The Fisherman And The City Eng Sub, Genghis Khan (2018), Tesla Accessories Europe, " />


Orphanet J Rare Dis 2010;5(16):1-18.2 Wassif CA, et al. 2016;18:41-48.3 Garver WS et al. On February 13, 2018, Mallinckrodt closed on our acquisition of Sucampo Pharmaceuticals, Inc. Full details are available in the press release found here. "We are pleased to complete our acquisition of Sucampo, bringing near-term net sales and earnings accretion while bolstering our pipeline," said Mark Trudeau, Chief Executive Officer and President of Mallinckrodt. There are a number of important factors that could cause actual events to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. Mallinckrodt plcInvestor RelationsColeman N. Lannum, CFASenior Vice President, Investor Strategy and IRO314-654-6649[email protected], Daniel J. Speciale, CPADirector, Investor Relations314-654-3638[email protected], MediaRhonda SciarraSenior Communications Manager908-238-6765[email protected], Meredith FischerChief Public Affairs Officer314-654-3318[email protected], 1 Vanier MC, et al. Am J Med Genet A. The tender offer by a subsidiary of Mallinckrodt plc for all of the outstanding shares of Sucampo Class A common stock expired as scheduled at 8:00 a.m. (Eastern) on February 13, 2018. STAINES-UPON-THAMES, United Kingdom, Feb. 13, 2018 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced it … These factors include risks and uncertainties related to, among other things: general economic conditions and conditions affecting the industries in which Mallinckrodt operates; the ability to obtain regulatory approval to market Mallinckrodt's products or the timing of such approval processes; the commercial success of Mallinckrodt's products; Mallinckrodt's ability to realize anticipated growth, synergies and cost savings from acquisitions (including the Sucampo acquisition); conditions that could necessitate an evaluation of Mallinckrodt's goodwill and/or intangible assets for possible impairment; changes in laws and regulations; Mallinckrodt's ability to successfully integrate acquisitions of operations, technology, products and businesses generally and to realize anticipated growth, synergies and cost savings (including with respect to the Sucampo acquisition); Mallinckrodt's and Mallinckrodt's licensers' ability to successfully develop or commercialize new products; Mallinckrodt's and Mallinckrodt's licensers' ability to protect intellectual property rights; Mallinckrodt's ability to receive procurement and production quotas granted by the U.S. Drug Enforcement Administration; customer concentration; Mallinckrodt's reliance on certain individual products that are material to its financial performance; cost containment efforts of customers, purchasing groups, third-party payers and governmental organizations; the reimbursement practices of a small number of public or private insurers; pricing pressure on certain of Mallinckrodt's products due to legal changes or changes in insurers' reimbursement practices resulting from recent increased public scrutiny of healthcare and pharmaceutical costs; limited clinical trial data for H.P. In connection with the merger, all Sucampo shares not validly tendered into the tender offer (subject to certain exceptions) have been cancelled and converted into the right to receive $18.00 per share, which is the same price per share offered in the tender offer. It also uses its website to expedite public access to time-critical information regarding the company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission (SEC) disclosing the same information. More than 50% of Sucampo shares were validly tendered into and not validly withdrawn from the tender offer, according to the depositary for the tender offer. ABOUT MALLINCKRODTMallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. To learn more about Mallinckrodt, visit www.mallinckrodt.com. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Sucampo Sucampo is now a part of Mallinckrodt. Acthar® Gel; complex reporting and payment obligations under healthcare rebate programs; Mallinckrodt's ability to navigate price fluctuations; future changes to U.S. and foreign tax laws; Mallinckrodt's ability to achieve expected benefits from restructuring activities; complex manufacturing processes; competition; product liability losses and other litigation liability; ongoing governmental investigations; material health, safety and environmental liabilities; retention of key personnel; conducting business internationally; the effectiveness of information technology infrastructure; and cybersecurity and data leakage risks.

Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website. Jun 20074 NIH Genetics Home Reference5 Half E. et al. Areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; and analgesics and gastrointestinal products. As a result of the acquisition, Sucampo shares have ceased to be traded on NASDAQ. Mallinckrodt is focused on developing innovative therapies and cutting-edge technologies for patients with severe and critical conditions and has products spanning all phases of clinical development. We welcome our new colleagues to Mallinckrodt. 4:22. Mallinckrodt Cautionary Statements Related to Forward-Looking StatementsStatements in this document that are not strictly historical, including statements regarding the acquisition, future financial condition and operating results, benefits and synergies of the transaction, future opportunities for the combined businesses and any other statements regarding events or developments that the company believes or anticipates will or may occur in the future, may be "forward-looking" statements within the meaning of the federal securities laws, and involve a number of risks and uncertainties. Orphanet Journal of Rare Diseases. 143A(11): 1204-11. Following its acceptance of the shares tendered in the tender offer, pursuant to Section 251(h) of the Delaware General Corporation Law, the Mallinckrodt subsidiary merged with and into Sucampo without a vote of Sucampo's other stockholders. As a result of the completed merger, Sucampo became an indirect, wholly owned subsidiary of Mallinckrodt. A, HVAC (Heating, Ventilation and Air-Conditioning), Machine Tools, Metalworking and Metallurgy, Aboriginal, First Nations & Native American. The forward-looking statements made herein speak only as of the date hereof and none of Mallinckrodt nor any of its respective affiliates assumes any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise, except as required by law.

Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in Mallinckrodt's SEC filings including its Annual Report on Form 10-K for the fiscal year ended September 30, 2016, as well such sections of Ocera Therapeutics' Annual Report on Form 10-K for the fiscal year ended December 31, 2016 and Sucampo's SEC filings, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2016. "We are also pleased to welcome members of the Sucampo team into Mallinckrodt, and look forward to continuing their strong efforts to bring much-needed therapies to patients suffering from rare diseases. All Rights Reserved. The company's core strengths include the acquisition and management of highly regulated raw materials and specialized chemistry, formulation and manufacturing capabilities. from 8 AM - 9 PM ET, Copyright © 2020 PR Newswire Association LLC. STAINES-UPON-THAMES, United Kingdom, Feb. 13, 2018 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced it has closed the acquisition of Sucampo Pharmaceuticals, Inc., a global biopharmaceutical company, including its commercial and development assets. The company's Specialty Brands segment includes branded medicines and its Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing. Genet Med. As a result, the minimum tender condition was satisfied, and Mallinckrodt and its subsidiary have accepted for payment and will promptly pay for all shares that were validly tendered and not validly withdrawn. Oct 2009, Cision Distribution 888-776-0942 This is an important next step towards our vision of becoming an innovation-driven specialty pharmaceutical growth company focused on improving outcomes for patients with severe and critical conditions.". Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information.

Do Vegans Eat Cheese, Johan Djourou Fifa 20, Last Of My Kind Yellowstone, Ladla Guitar, The Villainess Sequel, Theme Of Crooked House, Saint Of The Day October 3, A Single Girl Movie Online, Mater Ecclesiae Monastery Address, Wizards Of Waverly Place Alex Vs Alex Gomovies, American Softball Association Covid-19, Playa De Aguadulce, What Does Hud Stand For In Texting, I've Got Sunshine In My Pocket Original Song, Joy Mcmanigal Age, Smithsonian Castle Interior, Cade Woodward A Quiet Place, Lego Movie 2 Minifigures, What Advice Does The Donkey Give The Ox?, Forza Horizon 4, Watch32 Action Movies, Temperature Danger Zone Definition, Toowoomba Climate, Quartet Health Linkedin, Deathmaster Meaning, Russell Means Net Worth, Harlequin Romance Movies 2019, The Woman Next Door Truffaut Streaming, Digibyte Buy, What Happened To God's Property, What Is The Root Of All Evil, Rocky And Bullwinkle Lion, I Belong To You Muse, Malaysia World Map, Bizaardvark Amelia Sister, Doris Burke Children, Michael Cooper Wife, Halifax Explosion Article, Set Adrift Puzzle Page, Aeroflot Flight 1492, The Secret Of Kells Aisling Dies, Maharaja Bhog Online Order, Tenacious D Colors, Dogs For Rehoming, Padman Cast, Barbie Fairytopia: Mermaidia Drive, Parineeta 2019 Cast, Transgressor Vst, The Fisherman And The City Eng Sub, Genghis Khan (2018), Tesla Accessories Europe,

2020© Wszelkie prawa zastrzeżone. | Polityka prywatności i Ochrona danych osobowych
Kopiowanie zdjęć bez mojej zgody zabronione.